First in our summer Research Round Up podcast series, Charles Loprinzi, MD, and Ezra Cohen, MD, unpack some of science highlights from the 2015 ASCO Annual Meeting.
Patient advocate Diana Chingos wanted to attend the 2015 ASCO Annual Meeting to learn about the latest cancer research. After four intense days of posters and presentations, she left Chicago with a mountain of new knowledge and four key insights.
In January, Randy Hillard was part of the U.S. Food and Drug Administration committee that considered the first application for a “biosimilar” medication. In this guest post, he describes patients’ role in the drug approval process and how the committee’s decision could influence cancer care in the future.
In this podcast, experts Charles Ryan, MD, and Thomas Powles, MD, talk about bladder cancer treatment, including some of the new approaches that are being developed.
Two out of three people now live at least five years after being diagnosed with cancer, but there is still more to be done. Researchers at the 2015 ASCO Annual Meeting showed how new treatment options can continue to improve and lengthen the lives of people with both rare and common cancers.
Is More Extensive Surgery Better for Early-Stage Oral Cancer? – Research from the 2015 ASCO Annual Meeting
Doctors worldwide have struggled with this question for decades. A new study presented today at the 2015 ASCO Annual Meeting provides clarification on whether lymph nodes should be removed before or after cancer has been detected in the nodes of people with early-stage oral cancer.
This year, President Obama has focused attention on treatments and tools that help doctors tailor medical care for individual patients. Research presented at the 2015 ASCO Annual Meeting shows how targeted therapies can be used to improve the care of people with a number of different types of blood cancer.
Immunotherapy is one of the hottest topics in cancer research. This year, focus at the ASCO Annual Meeting has been on a type of immunotherapy called PD-1 inhibitors. Learn how these drugs may help improve the treatment of head and neck, liver, and lung cancers.
A recent study shows that people who took a form of vitamin B3 called nicotinamide developed fewer non-melanoma skin cancers. In this podcast, Patricia A. Ganz, MD, discusses this study and what it means for people at risk for skin cancer.
From May 29 to June 2, 30,000 oncology professionals from around the world will meet to discuss the latest in cancer research. Find out how this knowledge will create better ways of caring for people with cancer in the future.